Next on tap for Meridian Bioscience‘s (NASDAQ:VIVO) illumigene molecular diagnostic testing platform is a test for Mycoplasma pneumonia, an infection of the lungs. The illumigene Mycoplasma test is ...
Diagnostic test maker Meridian Bioscience (NASDAQ:VIVO) has received Australian regulatory clearance of a molecular test for group B streptococcus. The test is part of Cincinnati-area Meridian’s ...
Meridian Bioscience Inc (NASDAQ: VIVO) has agreed to acquire the North American BreathTek business from Otsuka America Pharmaceutical Inc for $20 million in cash. The transaction will close in ...
Meridian Bioscience, Inc.: Magellan Diagnostics, Inc. Expands Voluntary Recall of LeadCare Test Kits
Customers should discontinue use of all LeadCare Test Kits lots identified as part of the recall and quarantine remaining inventory. Distributors should stop distribution of all LeadCare Test Kits ...
Meridian Bioscience (VIVO) is a $900 million provider of diagnostic test kits for gastrointestinal and respiratory infectious diseases. The company is expected to grow sales 18% this year to $300 ...
Meridian Bioscience, Inc. announced it has completed an amendment to the license agreement with Eiken Chemical Co., Ltd., Japan, for its “LAMP” (Loop-mediated Isothermal Amplification) technology for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results